[1]
|
Le Rhun, E., Preusser, M. and Roth, P. (2019) Molecular Targeted Therapy of Glioblastoma. Cancer Treatment Reviews, 80, 101896. https://doi.org/10.1016/j.ctrv.2019.101896
|
[2]
|
Louis, D.N., Perry, A., Reifenberger, G., et al. (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Summary. Acta Neuropathologica, 131, 803-820.
https://doi.org/10.1007/s00401-016-1545-1
|
[3]
|
王忠诚. 王忠诚神经外科学[M]. 第2版. 武汉: 湖北科学技术出版社, 2015: 515-520.
|
[4]
|
Stupp, R., Hegi, M.E., Mason, W.P., et al. (2009) Effects of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-Year Analysis of the EORTC-NCIC Trial. The Lancet Oncology, 10, 459-466.
|
[5]
|
Chamberlain, M.C. (2011) Radiographic Patterns of Relapse in Glioblastoma. Journal of Neuro-Oncology, 101, 319-323. https://doi.org/10.1007/s11060-010-0251-4
|
[6]
|
Jennifer, L.S., Gordon, L., Jenny, L.S., et al. (2018) Stereotactic Radiosurgery and Hypofractionated Radiotherapy for Glioblastoma. Neurosurgery, 82, 24-34. https://doi.org/10.1093/neuros/nyx115
|
[7]
|
Perry, J.R., Laperriere, N., O’Callaghan, C.J., et al. (2017) Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. The New England Journal of Medicine, 376, 1027-1037.
|
[8]
|
Attenello, F.J., Mukherjee, D., Datoo, G., et al. (2008) Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience. Annals of Surgical Oncology, 15, Article No. 2887.
https://doi.org/10.1245/s10434-008-0048-2
|
[9]
|
Bregy, A., Shah, A.H., Diaz, M.V., et al. (2013) The Role of Gliadel Wafers in the Treatment of High-Grade Gliomas. Expert Review of Anticancer Therapy, 13, 1453-1461. https://doi.org/10.1586/14737140.2013.840090
|
[10]
|
McGirt, M.J., Than, K.D., Weingart, J.D., et al. (2009) Gliadel (BCNU) Wafer plus Concomitant Temozolomide Therapy after Primary Resection of Glioblastoma Multiforme. Journal of Neurosurgery, 110, 583-538.
https://doi.org/10.3171/2008.5.17557
|
[11]
|
Buonerba, C., Di Lorenzo, G., Marinelli, A., et al. (2011) A Comprehensive Outlook on Intracerebral Therapy of Malignant Gliomas. Critical Reviews in Oncology/Hematology, 80, 54-68.
https://doi.org/10.1016/j.critrevonc.2010.09.001
|
[12]
|
Buckner, J.C., Shaw, E.G., Pugh, S.L., et al. (2016) Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. The New England Journal of Medicine, 374, 1344-1355. https://doi.org/10.1056/NEJMoa1500925
|
[13]
|
Weller, M. and Rhun, E.L. (2020) How Did Lomustine Become Standard of Care in Recurrentgliobl Astoma? Cancer Treatment Reviews, 87, 102029. https://doi.org/10.1016/j.ctrv.2020.102029
|
[14]
|
Alexander, B.M., Ba, S., Berger, M.S., et al. (2018) Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clinical Cancer Research, 24, 737-743. https://doi.org/10.1158/1078-0432.CCR-17-0764
|
[15]
|
Friedman, H.S., Prados, M.D., Wen, P.Y., et al. (2009) Bevacizumab Alone and in Combination with Irinotecan in Recurrent Glioblastoma. Journal of Clinical Oncology, 27, 4733-4740. https://doi.org/10.1200/JCO.2008.19.8721
|
[16]
|
Wick, W., Gorlia, T., Bendszus, M., et al. (2017) Lomustine and Bevacizumab in Progressive Glioblastoma. The New England Journal of Medicine, 377, 1954-1963. https://doi.org/10.1056/NEJMoa1707358
|
[17]
|
Zhang, H., Wang, R., Yu, Y., et al. (2019) Glioblastoma Treatment Modalities besides Surgery. Journal of Cancer, 10, 4793-4806. https://doi.org/10.7150/jca.32475
|
[18]
|
Heimberger, A.B., Hlatky, R., Suki, D., et al. (2005) Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients. Clinical Cancer Research, 11, 1462-1466.
https://doi.org/10.1158/1078-0432.CCR-04-1737
|
[19]
|
Sasmita, A.O., Wong, Y.P. and Ling, A.P.K. (2018) Biomarkers and Therapeutic Advances in Glioblastoma Multiforme. Asia-Pacific Journal of Clinical Oncology, 14, 40-51. https://doi.org/10.1111/ajco.12756
|
[20]
|
Del Vecchio, C.A., Li, G. and Wong, A.J. (2012) Targeting EGF Receptor Variant III: Tumor-Specific Peptide Vaccination for Malignant Gliomas. Expert Review of Vaccines, 11, 133-144. https://doi.org/10.1586/erv.11.177
|
[21]
|
Swartz, A.M., Li, Q.J. and Sampson, J.H. (2014) Rindopepimut: A Promising Immunotherapeutic for the Treatment of Glioblastoma Multiforme. Immunotherapy, 6, 679-690. https://doi.org/10.2217/imt.14.21
|
[22]
|
Yagiz, K., Huang, T.T., Espinoza, F.L., et al. (2016) Toca 511 plus 5-Fluorocytosine in Combination with Lomustine Shows Chemotoxic and Immunotherapeutic Activity with No Additive Toxicity in Rodent Glioblastoma Models. Neuro-Oncology, 18, 1390-1401. https://doi.org/10.1093/neuonc/now089
|
[23]
|
Cloughesy, T.F., Landolfi, J., Hogan, D.J., Bloomfield, S., et al. (2016) Phase 1 Trial of Vocimagene Amiretrorepvec and 5-Fluorocytosine for Recurrent High-Grade Glioma. Science Translational Medicine, 8, 341-375.
https://doi.org/10.1126/scitranslmed.aad9784
|
[24]
|
Crommentuijn, M.H.W., Kantar, R., Noske, D.P., et al. (2016) Systemically Administered AAV9-sTRAIL Combats Invasive Glioblastoma in a Patient-Derived Orthotopic Xenograft Model. Molecular Therapy Oncolytics, 3, 16017.
https://doi.org/10.1038/mto.2016.17
|
[25]
|
Gray, S.J., Matagne, V., Bachaboina, L., et al. (2011) Preclinical Differences of Intravascular AAV9 Delivery to Neurons and Glia: A Comparative Study of Adult Mice and Nonhuman Primates. Molecular Therapy, 19, 1058-1069.
|
[26]
|
Natsume, A. and Yoshida, J. (2008) Gene Therapy for High-Grade Glioma: Current Approaches and Future Directions. Cell Adhesion & Migration, 2, 186-191. https://doi.org/10.4161/cam.2.3.6278
|
[27]
|
Hong, Y.K., Joe, Y.A., Yang, Y.J., et al. (2000) Potentials and Limitations of Adenovirus-p53 Gene Therapy for Brain Tumors. Journal of Korean Medical Science, 15, 315-322. https://doi.org/10.3346/jkms.2000.15.3.315
|
[28]
|
Stupp, R., Taillibert, S., Kanner, A., et al. (2017) Effect of Tumor-Treating Fields plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients with Glioblastoma: A Randomized Clinical Trial. JAMA, 318, 2306-2316. https://doi.org/10.1001/jama.2017.18718
|
[29]
|
Kirson, E.D., Gurvich, Z., Schneiderman, R., et al. (2004) Disruption of Cancer Cell Replication by Alternating Electric Fields. Cancer Research, 64, 3288-3295. https://doi.org/10.1158/0008-5472.CAN-04-0083
|
[30]
|
Fabian, D., Eibl, G.P., Alnahhas, I., et al. (2019) Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review. Cancers (Basel), 11, 174. https://doi.org/10.3390/cancers11020174
|
[31]
|
Chinnaiyan, P., Won, M., Wen, P.Y., et al. (2018) A Randomized Phase II Study of Everolimus in Combination with Chemoradiation in Newly Diagnosed Glioblastoma: Results of NRG Oncology RTOG 0913. Neuro-Oncology, 20, 666-673. https://doi.org/10.1093/neuonc/nox209
|
[32]
|
Vasilev, A., Sofi, R., Rahman, R., et al. (2020) Using Light for Therapy of Glioblastoma Multiforme (GBM). Brain Sciences, 10, 75. https://doi.org/10.3390/brainsci10020075
|
[33]
|
Baptista, M.S., Cadet, J., Di Mascio, P., et al. (2017) Type I and Type II Photosensitized Oxidation Reactions: Guidelines and Mechanistic Pathways. Photochemistry and Photobiology, 93, 912-919. https://doi.org/10.1111/php.12716
|
[34]
|
Mahmoudi, K., Garvey, K.L., Bouras, A., et al. (2019) 5-Aminolevulinic Acid Photodynamic Therapy for the Treatment of High-Grade Gliomas. Journal of Neuro-Oncology, 141, 595-607. https://doi.org/10.1007/s11060-019-03103-4
|
[35]
|
Robertson, C.A., Evans, D.H. and Abrahamse, H. (2009) Photodynamic Therapy (PDT): A Short Review on Cellular Mechanisms and Cancer Research Applications for PDT. Journal of Photochemistry and Photobiology B: Biology, 96, 1-8. https://doi.org/10.1016/j.jphotobiol.2009.04.001
|
[36]
|
Schwartz, C., Ruhm, A., Tonn, J.-C., et al. (2015) Interstital Photodynamic Therapy of De-Novo Glioblastoma Multiforme WHO IV. Neuro-Oncology, 17, 214-220. https://doi.org/10.1093/neuonc/nov235.25
|
[37]
|
Stylli, S.S., Kaye, A.H., MacGregor, L., et al. (2005) Photodynamic Therapy of High Grade Glioma—Long Term Survival. Journal of Clinical Neuroscience, 12, 389-398. https://doi.org/10.1016/j.jocn.2005.01.006
|
[38]
|
Muller, P.J. and Wilson, B.C. (2006) Photodynamic Therapy of Brain Tumors—A Work in Progress. Lasers in Surgery and Medicine, 38, 384-389. https://doi.org/10.1002/lsm.20338
|
[39]
|
Akimoto, J., Haraoka, J. and Aizawa, K. (2012) Preliminary Clinical Report on Safety and Efficacy of Photodynamic Therapy Using Talaporfin Sodium for Malignant Gliomas. Photodiagnosis and Photodynamic Therapy, 9, 91-99.
https://doi.org/10.1016/j.pdpdt.2012.01.001
|
[40]
|
Rosenthal, M.A., Kavar, B., Uren, S., et al. (2003) Promising Survival in Patients with High-Grade Gliomas Following Therapy with a Novel Boronated Porphyrin. Journal of Clinical Neuroscience, 10, 425-427.
|